Adicet Bio Inc reports results for the quarter ended in January - Earnings Summary

ADICET Bio

13/08/2024 13:15

* Adicet Bio Inc  ACET.OQ  reported a quarterly adjusted
loss
of 33 cents​​ per share for the quarter ended in January, higher
than the same quarter last year, when the company reported EPS
of -75 cents.  The mean expectation of eight analysts for the
quarter was for a loss of 36 cents per share. Wall Street
expected results to range from -41 cents to -30 cents per share.
    * Reported revenue was zero​; analysts expected $625.00
thousand. 
    * Adicet Bio Inc's reported EPS for the quarter was a loss
of 33
cents​.
    * The company reported a quarterly loss of $29.9 million.
    * Adicet Bio Inc shares had risen by 5.0% this quarter and
lost 32.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 4.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Adicet Bio Inc is
$7.00 
This summary was machine generated from LSEG data August 13 at
12:15 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.36          -0.33          Beat
 Mar. 31 2024      -0.39          -0.35          Beat
 Dec. 31 2023      -0.69          -0.69          Met
 Sep. 30 2023      -0.74          -1.16          Missed